Locust Walk analyzed the evolving landscape of China’s biotech out-licensing market and its impact on global dealmaking.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings.
Locust Walk’s Overview of AI in Biotech report discusses how AI has profoundly impacted drug discovery and the pharmaceutical industry in the last five years, with AI-derived assets representing nearly half of the preclinical pipeline.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Year-In-Review Report applies the latest data to analyze current activities in the life sciences deal landscape.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Year In Review Report applies the latest data to analyze current activities in the life sciences deal landscape.
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Year End Market Conditions Report applies the latest data to analyze current activities in the life sciences deal landscape.
Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand
Induced pluripotent stem cell (iPSC) research has encapsulated a global market of scientists, clinicians, and investors and has quickly become the foundation for new regenerative medicines.
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our 2020 Year End Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal landscape.
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2019 Annual Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal landscape.